文献速递创面修复

生物合成补片与合成补片在肿瘤性腹壁疝修补中的比较

Biosynthetic Versus Synthetic Mesh in Oncologic Ventral Hernia Repair.
PubMed 文献 · Plast Reconstr Surg · 2026-01-22

本研究回顾性分析2010至2023年因肿瘤切除后行腹壁疝修补的207例患者,比较生物合成补片(102例)与合成补片(105例)的并发症率和疝复发率。结果显示两组并发症率(24% vs 18%,p=0.3)和复发率(8.8% vs 6.7%,p>0.6)无显著差异,生物合成补片可作为高危患者的合理替代选择。

要点

  • 生物合成补片与合成补片在肿瘤性腹壁疝修补中并发症率和复发率无显著差异。
  • 双侧腹外斜肌松解和肌后补片放置与降低疝复发风险独立相关。
  • 生物合成补片可作为合成补片的高危患者合理替代选择。

核心结论

  • 在肿瘤性腹壁疝修补的高危患者中,生物合成补片可视为合成补片的合理替代。

研究设计与样本

  • 回顾性研究,纳入2010至2023年因肿瘤切除后行腹壁疝修补的207例患者(生物合成补片102例,合成补片105例)。

主要发现

  • 总体并发症率:生物合成补片组24%,合成补片组18%,差异无统计学意义(p=0.3)。
  • 疝复发率:生物合成补片组8.8%,合成补片组6.7%,差异无统计学意义(p>0.6)。
  • 伤口II-IV类亚组分析结果一致。
  • 术后两年内,合成补片相比生物合成补片未显著降低疝复发风险(sHR 0.66;95% CI 0.27-1.59;p=0.4)。
  • 双侧腹外斜肌松解(sHR 0.31;95% CI 0.11-0.87;p=0.026)和肌后补片放置(sHR 0.08;95% CI 0.02-0.35;p<0.001)显示保护作用。

临床怎么用

  • 对于肿瘤性腹壁疝高危患者,生物合成补片可作为合成补片的替代选择。
  • 在修补技术中,可考虑采用肌后补片放置或双侧腹外斜肌松解以降低复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ventral hernia repair in oncologic patients is challenging due to poor tissue quality, immunosuppression, malnutrition, and prior operations. Limited data exists comparing the outcomes of biosynthetic (Poly-4-hydroxybutyrate) and synthetic mesh in this population. This study aims to assess the outcomes in patients who undergo hernia repair using one of two mesh types. METHODS: Patients undergoing ventral hernia repair by the Plastic and Reconstructive Surgery service and general surgery after oncologic resection from 2010 to 2023 were included, with patient records reviewed and cases identified in a prospectively maintained database by the Plastic and Reconstructive Service. Repairs were done in a retrorectus, underlay, or onlay fashion with either biosynthetic or synthetic mesh. Primary endpoints included complication rates (hematoma, infection/cellulitis, wound dehiscence, abscess, seroma) and hernia recurrence. RESULTS: 207 patients underwent repair (102 biosynthetic, 105 synthetic) and were included. Baseline demographics were similar between groups. No significant difference was observed in complication rates (biosynthetic: 24%, synthetic: 18%; p=0.3). Hernia recurrence was noted in 8.8% of biosynthetic and 6.7% of synthetic mesh cases (p>0.6). Subgroup analysis of wound classes II-IV showed consistent results. Up to two years postoperatively, synthetic mesh did not significantly reduce hernia recurrence risk compared to biosynthetic mesh (Subdistribution Hazard Ratio (sHR): 0.66; 95% CI, 0.27-1.59; p=0.4). Bilateral external abdominal oblique release (sHR: 0.31; 95% CI, 0.11-0.87, p=0.026) and retromuscular mesh placement (sHR: 0.08; 95% CI, 0.02, 0.35, p<0.001) exhibited a protective role. CONCLUSION: Biosynthetic mesh can be considered a reasonable alternative to synthetic mesh in this high-risk population.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Levy J, Wagner BD, Roberts A, et al. Biosynthetic Versus Synthetic Mesh in Oncologic Ventral Hernia Repair. Plast Reconstr Surg. 2026. PMID: 41604244. doi:10.1097/PRS.0000000000012848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。